NEWS

How our value-driven FIT approach can increase your process reliability and patient safety

3 October 2023
Drug Substance
Fill Finish
Paul Osbourne
Global Change Facilitator

The new revision of EudraLex Annex 1 aims to give guidance on the manufacture of sterile drug products. However, it also suggests that some of its principles and guidance could (and perhaps should) be used to support the manufacture of low bioburden biologicals (active pharmaceutical ingredients/drug substance). Manufacturing a low bioburden biologicals drug substance is subject to the requirements to mitigate the risks of viable and non-viable contaminants.

Annex 1 includes a comprehensive list of criteria for designing and operating sterilizing-grade filters. The list includes an expectation that the filtration system is designed for pre- and post-use filter integrity testing (FIT).

While Annex 1 is relatively explicit about FIT requirements for drug product facilities, no clear guidance is available on FIT requirements in drug substance manufacturing.

Our new paper—A risk-based approach to filter integrity testing requirements for biologics drug substance manufacturersaims to fill that gap with a risk-based, value-driven approach for FIT testing of sterilizing grade filters used to manufacture low bioburden drug substances.

We used a systematic risk assessment tool designed to mitigate product, process, patient, and business risk, and evaluate multiple categories of sterile filtration operations used in a common drug substance manufacturing facility. It illustrates where higher-risk mitigation controls are recommended and where FIT provides little or no value in terms of risk mitigation.

Driving alignment across industry

Our paper also includes a comprehensive decision tree evaluation process to determine which sterilizing-grade filters should undergo integrity testing when used in typical drug substance manufacturing schemes. The goal throughout is to help drive alignment across industry and identify adaptable best practices for FIT.

The findings of this study and the decision tree model were compared to current industry practice through a survey. Strong alignment was evident, suggesting the model could be used by drug substance manufacturers to develop a robust strategy for FIT, which is consistent with regulatory guidance—specifically EudraLex Annexes 1 and 2.

The risk-based approach is recommended to avoid dilution of effort on unnecessary FIT controls and target critical FIT use cases that increase process reliability and patient safety outcomes.

By considering the true value and mitigation provided by each FIT performed, drug substance manufacturing sites can focus limited resources on those areas best positioned to improve process execution, product quality, and patient safety outcomes. For more information, download the paper here and contact Paul Osborne, Global Change Facilitator, at paul.osborne@biophorum.com

PODCAST
The implementation of Annex 1 and beyond – how BioPhorum supports members now and in the future
NEWS
Survey of industry practice for PUPSIT in 2024
Medication
NEWS
Using a closure analysis method to reduce CGT contamination risks
NEWS
The results are in – BioPhorum’s survey on sterile filtration integrity testing
NEWS
Introducing BioPhorum’s Closure Playbook 

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.

Quality

BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.

Regulatory-CMC

Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Partner

Supply Partner is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.

Sustainability

Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

DOWNLOAD
An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
EXTERNAL-RESOURCE
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
DOWNLOAD
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
DOWNLOAD
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
DOWNLOAD
Digital Plant Maturity Model 3.0
Investigation Digital Workstreams
DOWNLOAD
Peer to peer practical guidance on remote inspections and audits
PODCAST
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
BioPhorum roundals on sugical gloves
DOWNLOAD
A visionary strategic framework for future patient-centric outbound biopharmaceutical supply chains
DNA and Earth on blue background
DOWNLOAD
A vision for the biopharmaceutical industry’s inbound supply chain
Lightbulb And Icons On Colourful Background
DOWNLOAD
BioPhorum environmental sustainability roadmap 2022
Technology Roadmap V 2.0
DOWNLOAD
BioPhorum Technology Roadmapping roadmap vision 2.0

Publications

Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.

Webinars

Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.

Podcasts

BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.

Tools

A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

WEBINAR
Bioreactivity testing in single-use system biomanufacturing
WEBINAR
Bioreactivity testing in single-use system biomanufacturing
WEBINAR
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
DOWNLOAD
Digital Plant Maturity Model 3.0
WEBINAR
Bioreactivity testing in single-use system biomanufacturing